Revenue Performance - Total revenue for Q1 2025 increased by $180 thousand, or 0.3%, to $61.3 million compared to Q1 2024[4] - Total revenue for Q1 2025 was $61,268,000, a slight increase of 0.3% compared to $61,088,000 in Q1 2024[24] - Sales revenue decreased to $52,469,000 in Q1 2025 from $53,307,000 in Q1 2024, representing a decline of 1.6%[24] - Rental revenue increased to $8,799,000 in Q1 2025, up 13.1% from $7,781,000 in Q1 2024[24] - Lymphedema products accounted for 83% of total revenue in Q1 2025, down from 86% in Q1 2024[27] - The company expects full year 2025 total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year[11] Profitability - Gross profit for Q1 2025 increased by $1.9 million, or 4%, to $45.3 million, with a gross margin of 74% compared to 71% in Q1 2024[5] - Gross profit for Q1 2025 was $45,346,000, an increase of 4.4% compared to $43,429,000 in Q1 2024[24] - Adjusted EBITDA loss for Q1 2025 was $0.3 million, compared to positive Adjusted EBITDA of $1.0 million in Q1 2024[9] - Adjusted EBITDA for Q1 2025 was $(259,000), a decrease of 125% from $1,033,000 in Q1 2024[28] - The company now expects full year 2025 adjusted EBITDA in the range of $32 million to $34 million, compared to adjusted EBITDA of $37.1 million in 2024[12] Expenses and Losses - Net loss for Q1 2025 was $3.0 million, or $(0.13) per diluted share, compared to a net loss of $2.2 million, or $(0.09) per diluted share, in Q1 2024[8] - Net loss for Q1 2025 was $2,974,000, compared to a net loss of $2,209,000 in Q1 2024, reflecting a 34.7% increase in losses[24] - Operating expenses increased by $3.5 million, or 8%, to $49.9 million, primarily due to planned strategic investments[7] - Operating expenses rose to $49,888,000 in Q1 2025, up 7.4% from $46,393,000 in Q1 2024[24] Cash and Stock Repurchase - As of March 31, 2025, the company had $83.6 million in cash and $25.5 million of outstanding borrowings under its credit agreement[10] - Cash at the end of Q1 2025 was $83,619,000, a decrease from $94,367,000 at the beginning of the period[26] - The company repurchased $10.0 million of stock during Q1 2025 under its share repurchase program[6]

MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted ...

MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Tho ...

MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. A live audio web ...

MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. A live audio we ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2024 Earnings Conference Call February 18, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Max Smock - William Blair Adam Maeder - Piper Sandler Iseult McMahon - BTIG Kyle Bauser - B. Riley Securities Suraj Kalia - Oppenheimer & Company Operator Please standby. Welcome, ladies and gentlemen, to the Fourth ...

Financial Results Announcement - Tactile Systems Technology, Inc. will release its fourth quarter and fiscal year 2024 financial results after market close on February 18, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results [2] Conference Call Details - Participants can join the call by dialing 877-407-3088 (international callers: 201-389-0927) and using access code 13751026 [2] - A live webcast will be available on the investor relations section of the Company's website [2] Replay Information - A replay of the conference call will be accessible for two weeks at 877-660-6853 (international callers: 201-612-7415) with the same access code [3] - The webcast will be archived on the Company's investor relations website [3] Company Overview - Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4] - The Company aims to improve the quality of life for patients by collaborating with clinicians to enhance clinical evidence and increase access to care [4]

Core Insights - Tactile Systems Technology, Inc. has launched its next-generation pneumatic compression platform, Nimbl, for both upper and lower extremity lymphedema treatment, expanding its availability across the U.S. [1][2] Product Features - Nimbl is the smallest pneumatic compression device of its kind, featuring a controller that is 68% lighter and 40% smaller than the previous generation [2] - The lower extremity garment uses 94% less hosing, enhancing transportability and ease of management [2] - Nimbl is the only basic pneumatic compression device with Bluetooth connectivity, allowing patients to track treatments and symptom progress via the Kylee™ digital application [2] Patient-Centric Design - The device is designed to be user-friendly and comfortable, promoting increased adherence to treatment [3] - Its compact design and reduced hose length facilitate easier transport within the home and during travel, improving the overall patient experience [3] Company Overview - Tactile Medical focuses on developing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4] - The company collaborates with clinicians to enhance clinical evidence, raise awareness, and improve patient care while reducing healthcare costs [4]

Company Overview - Tactile Systems Technology, Inc. (Tactile Medical) is a medical technology company focused on providing therapies for individuals with chronic disorders, particularly underserved conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [3]. Leadership Appointment - Laura King has been appointed to the Board of Directors of Tactile Medical and will also serve on the Audit and Compliance & Reimbursement Committees, effective January 13, 2025 [1]. - Ms. King brings over 22 years of experience from General Electric Company (GE), where she held various senior roles, including President & CEO of GE Healthcare's Global Interventional Business [2]. - Her previous leadership roles include co-founding BiaCure, Inc. and Elucent Medical, and serving as President & CEO of NeuWave Medical, which was acquired by Johnson & Johnson's MedTech division [2]. Strategic Impact - The appointment of Laura King is expected to enhance Tactile Medical's capabilities in developing innovative technologies aimed at improving patient care, particularly in the areas of lymphedema and airway clearance therapies [2]. - The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce healthcare costs, and improve the quality of life for patients [3].

Core Viewpoint - Tactile Systems Technology (TCMD) is currently identified as a strong value stock, supported by its favorable valuation metrics and earnings outlook [4][8]. Valuation Metrics - TCMD has a P/E ratio of 21.75, significantly lower than its industry's average P/E of 32.26 [4]. - The stock's P/B ratio stands at 2.10, compared to the industry's average P/B of 4.12, indicating solid valuation [5]. - TCMD's P/S ratio is 1.59, which is lower than the industry's average P/S of 3.03, suggesting it may be undervalued [6]. - The P/CF ratio for TCMD is 20.07, which is also below the industry's average P/CF of 23.27, further supporting the undervaluation thesis [7]. Investment Outlook - The combination of TCMD's strong earnings outlook and its attractive valuation metrics positions it as a compelling investment opportunity for value investors [8].